• Nintedanib (BIBF 1120): Strategic Angiokinase Inhibition in

  2026-07-17

  This thought-leadership article unpacks the mechanistic, experimental, and translational dimensions of Nintedanib (BIBF 1120)—a triple angiokinase inhibitor—using the lens of recent advances in ATRX-deficient glioma research. Drawing on both clinical and bench studies, it offers actionable guidance for researchers seeking to exploit angiogenesis inhibition in cancer and fibrotic disease models. The piece distinguishes itself from generic product overviews by integrating protocol nuances, competitive context, and a forward-looking perspective for translational teams.

• AO/PI Staining Solution: Next-Generation Cell Integrity Anal

  2026-07-16

  Explore how AO/PI Staining Solution, featuring advanced fluorescent DNA dyes, revolutionizes cell membrane integrity assays. This in-depth article uniquely bridges mechanistic insights from diabetic nephropathy research with rigorous assay optimization, offering new standards for accurate cell viability and live/dead discrimination.

• β-Pseudouridine: Structural Gatekeeper in RNA Dynamics and V

  2026-07-16

  Explore β-Pseudouridine as the C-glycoside isomer of uridine, revealing its unique role in RNA secondary structure stabilization and advanced mRNA vaccine engineering. This article delivers a deep dive into β-Pseudouridine’s mechanism, assay considerations, and future research frontiers.

• AO/PI Staining Solution: Precision Cell Viability for Transl

  2026-07-15

  Explore how AO/PI Staining Solution leverages dual fluorescent DNA dyes for highly accurate cell viability analysis, surpassing traditional assays. This in-depth article reveals practical innovations and protocol insights that advance research into inflammation, apoptosis, and disease modeling.

• Cabozantinib (XL184): Advanced Protocols and RCC Research Wo

  2026-07-15

  Cabozantinib (XL184) stands out as a multi-kinase inhibitor vital for dissecting adaptive signaling in renal cell carcinoma. This article translates the latest phosphoproteomic breakthroughs and experimental insights into actionable workflows, protocol refinements, and troubleshooting tips for researchers leveraging APExBIO’s high-purity Cabozantinib.

• ω-Agatoxin IVA TFA: Precision Cav2.1 Blocker for Synaptic Re

  2026-07-14

  ω-Agatoxin IVA TFA delivers nanomolar-specific inhibition of P/Q-type Cav2.1 calcium channels, revolutionizing synaptic transmission and epilepsy model workflows. Its unmatched selectivity and robust neuroprotection profile set it apart as an essential, reproducible reagent for advanced neuronal calcium current recording and translational research.

• Mitotic Checkpoint Complex Stabilizes Cdc20 on APC/C During

  2026-07-14

  This study elucidates how the Mitotic Checkpoint Complex (MCC) maintains Cdc20 association with the Anaphase-Promoting Complex/Cyclosome (APC/C) during mitosis, despite phosphorylation and ubiquitylation events that typically promote Cdc20 release. The findings clarify a central regulatory mechanism in cell division and have implications for protein phosphorylation analysis in mitotic checkpoint research.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Techn

  2026-07-13

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is designed to prevent unwanted protein degradation during extraction and analysis, especially in workflows sensitive to divalent cation chelation. This product is not suitable for experiments where EDTA-based inhibition is required or where DMSO is incompatible with downstream assays.

• SLC2A5-Fructose Metabolism as a Therapeutic Target in PCNSL

  2026-07-13

  This study applies single-cell multi-omics to primary CNS lymphoma (PCNSL), revealing that glucose deprivation and hypoxia within the tumor microenvironment drive SLC2A5-mediated fructose metabolism in both tumor cells and macrophages. The findings highlight SLC2A5 as a metabolic vulnerability, suggesting new avenues for therapeutic intervention in PCNSL.

• ω-Agatoxin IVA TFA: Precision Tools for Calcium Channel Diss

  2026-07-12

  Explore how ω-Agatoxin IVA TFA empowers high-fidelity Cav2.1 calcium channel research, with a focus on mechanistic selectivity, neurophysiological impact, and evidence-based assay design. Learn what sets this peptide inhibitor and APExBIO's formulations apart from standard approaches.

• Dual Luciferase Reporter Gene System: Precision in Gene Regu

  2026-07-10

  Unlock sensitive, reproducible, and high-throughput transcriptional regulation studies with the Dual Luciferase Reporter Gene System. By combining robust normalization and streamlined protocols, researchers can dissect complex gene expression networks such as those involved in plant immune balance or mammalian signaling, now with actionable troubleshooting insights.

• Specific Induction of RV-like Cardiomyocytes from hPSCs

  2026-07-09

  Saito et al. present a targeted protocol to derive right ventricular-like cardiomyocytes from human pluripotent stem cells by modulating BMP signaling during mesoderm induction. This methodological advance enables chamber-specific disease modeling and comparative studies of ventricular biology.

• Sodium Picosulfate: Mechanistic and Evidence Benchmarks in G

  2026-07-09

  Sodium Picosulfate is a stimulant laxative with a defined mechanism—electrolyte absorption inhibition and water secretion stimulation—enabling precise constipation modeling. Peer-reviewed and product-level evidence confirm its robust solubility, workflow flexibility, and impact on serum electrolytes, supporting its adoption in translational gut–brain axis research.

• B. pseudomallei BipD Redirects Host Mitophagy via CUL3 E3 Li

  2026-07-08

  This study reveals how the bacterial effector BipD from Burkholderia pseudomallei manipulates host mitophagy by co-opting the KLHL9/KLHL13/CUL3 E3 ubiquitin ligase complex to ubiquitinate IMMT, initiating mitochondrial clearance and aiding bacterial survival. The findings highlight a novel host-pathogen interaction mechanism with implications for understanding intracellular bacterial evasion and the broader relevance of ubiquitin pathway modulation.

• Intravesical p21 mRNA-LNP Therapy: A New Approach for Bladde

  2026-07-08

  This study introduces intravesical delivery of p21 mRNA-loaded lipid nanoparticles as a tumor suppressor replacement therapy for bladder cancer. The approach demonstrates robust local tumor suppression with minimal systemic exposure, highlighting a promising direction for localized mRNA-based cancer treatments.

7958 records 5/531 page Previous Next 12345 下5页 Last page